Audax Private Equity is solely focused on building leading middle market companies.

Audax Private Equity

Laborie Medical Technologies

Membership-based, non-insurance healthcare companies helping maintain a steady state of well being.

Preventive Healthcare

Bright Uro is focused on developing its investigational technology, Glean Urodynamics System (Glean), to reinvent urodynamic testing. The system eliminates the need for invasive catheters during monitoring, offering a wireless and catheter-free solution. The company obtained an exclusive IP license from the Cleveland Clinic for this innovative approach.The system comprises a single-use disposable sensor, a reusable meter for measuring urinary flow and volume, and software apps for both patients and clinicians. By providing critical information without invasive procedures, the company aims to enhance the accuracy of urodynamic testing, improve patient comfort, and increase clinic efficiency.The company aims to launch its Glean Urodynamics System in 2025.&nbsp;

Pushing the envelope in MedTech with emerging technologies

Next-gen Medical Devices

Novocuff, Inc. is a medical device company focused on improving pregnancy outcomes and reducing preterm births caused by Preterm Premature Rupture of Membranes (PPROM) and cervical shortening. The company has developed the Novocuff Cervical Control System (CCS), a device designed to stabilize and close the cervix, retain amniotic fluid, and sustain cervical length with the goal of extending pregnancy. This approach aims to address PPROM and cervical shortening, which are major contributors to preterm birth. Preterm birth, defined as delivery before 37 weeks of gestation, is a leading cause of infant death globally. According to the World Health Organization, preterm birth complications were responsible for approximately 1 million deaths in 2020. PPROM occurs in approximately 1%-4% of all pregnancies, with its incidence reaching as high as 13.9% in developing countries, as reported in a 2022 study. Founded in 2021, Novocuff is headquartered in Mountain View, California. The company has initiated two first-in-human clinical studies to investigate the device's effectiveness in treating PPROM and cervical shortening. Novocuff plans to begin a multi-center US pivotal clinical trial in early 2025 to further evaluate the device's efficacy and safety.
Key customers and partnerships
Novocuff has received support from several notable organizations in the healthcare and investment sectors. In July 2024, Laborie Medical Technologies Corp., a diagnostic and therapeutic medical technology company, invested in Novocuff. This partnership aligns with both companies' missions to improve healthcare for pregnant women and newborns worldwide. Additionally, Novocuff has garnered support from other prominent entities such as AXA IM Alts, Laerdal Million Lives Fund, RH Capital, Avestria Ventures, and March of Dimes, which participated in the company's Series A financing round in July 2024.

Bright Uro is an early-stage medical technology company. It is building the next generation of diagnostic devices for Urology. Utilizing advanced hardware, software, and data science can unlock new data streams and offer actionable insight for clinicians.

Currently, after surgical removal of tumors found in the bladder, a drug is instilled into the bladder via a catheter. This treatment method is inefficient and ineffective: Urinary bladder cancer has the highest recurrence rates among all types of cancer (70%). Using Vensica’s device, the drug will be instilled in a quick, pain-free procedure subsequent to the delivery of ultrasound to the urinary bladder. Ultrasound improves the uptake of the drug and its penetration into the bladder wall and is expected to improve the treatment and reduce recurrence rates.

Novocuff is a medical device firm that aims to improve pregnancy outcomes and reduce preterm deliveries caused by PPROM and cervical shortening.

I-O Urology provides a patient monitoring system for urology.

GIE Medical is a medical organization that specializes in fitness care, scientific device, fitness diagnostics.

iTind is an Israeli medical device company. Our company is dedicated to improving men’s healthcare and quality of life via effective, non-surgical solutions for Benign Prostatic Hyperplasia (BPH). The flagship iTind treatment for BPH currently has the EU CE Mark and is approved for sale in the European Union, UK, Israel, Australia, Brazil, and FDA cleared for use in the USA.

Laborie Medical Technologies is a global developer, manufacturer and marketer of innovative medical technology and consumables used for the diagnosis and treatment of Urinary and Fecal Incontinence, as well as other pelvic floor disorders in the Urology, Gynecology, and Colorectal fields. Laborie is owned by Audax Group Private Equity based in Boston, MA.

Laborie Medical Technologies Invests in Medical Technology Start-Up Novocuff

Transforming neurological care with innovation

Neurostimulation Tech

Companies that offer solutions for pain management, neuropathies, and related disorders and migraines.

Companies that provide solutions for Parkinson's disease, epilepsy, and speech and movement disorders.

Companies that offer treatments for depression, Alzheimer's, and other mental health-related disorders.

Companies that offer solutions for heart-related medical issues such as acute decompensated heart failure and high blood pressure.

Companies that offer solutions for urinary or fecal incontinence, autoimmune diseases and other functional impairments

Companies that offer solutions for hearing or vision impairment, sleep-related conditions, and other disorders, including obesity treatments.

Laborie Medical Technologies

Featured Industries

EDGE Insights

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless